Ciclesonide Market - Forecast(2024 - 2030)

Report Code: HCR 1505 Report Format: PDF + Excel

Ciclesonide Market Overview

The Ciclesonide Market size is estimated to reach $671.7 million by 2027, growing at a CAGR of 2.1% during the forecast period 2022-2027. Ciclesonide is a glucocorticoid utilized to treat obstructive airway ailments, asthma and allergic rhinitis. Ciclesonide brand names include Alvesco for asthma and Omnaris, Omniair, Zetonna and Alvesco for hay fever in the U.S. and Canada. Ciclesonide price is about $296 for Alvesco inhalation aerosol (CFC free 80 mcg/inh) for a supply of 6.1 grams. Considering the ciclesonide mechanism of action, the body transforms ciclesonide to des ciclesonide, which is the active kind of medication. The Ciclesonide market in the U.S is being fuelled by the increasing predominance of asthma and allergy rhinitis. Ciclesonide side effects include a hoarse voice, sore throat and oral. The increasing pollution across the world resulting in asthma symptoms is set to drive the Ciclesonide Market. The surging application of medication with the ciclesonide brand name as a preventer for asthma is set to propel the growth of the Ciclesonide Industry during the forecast period 2022-2027. This represents the Ciclesonide Industry Outlook.

Ciclesonide Market Report Coverage

The “Ciclesonide Market Report - Forecast (2022-2027)” by IndustryARC, covers an in-depth analysis of the following segments in the Ciclesonide Market.

By Indication: Asthma and Allergic Rhinitis.
By End-user: Adults and Children.
By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest Of The World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America (Ciclesonide market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the great predominance of asthma and allergy rhinitis fuelling the ciclesonide market in the U.S in the North American region.
  • Ciclesonide Market growth is being driven by the heightening application of medication with the ciclesonide brand name to avert the symptoms of asthma like wheezing and shortness of breath. However, the accessibility of certain additional medicine providing superior treatment for allergy rhinitis and asthma impeding the acceptance of ciclesonide is one of the major factors hampering the growth of the Ciclesonide Market.
  • Ciclesonide Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Ciclesonide Market report.
Ciclesonide Market: Market Share (%) by Region, 2021
Ciclesonide Market
For More Details on This Report - Request for Sample

Ciclesonide Market Segment Analysis - by Indication

The Ciclesonide Market based on indication can be further segmented into Asthma and Allergic Rhinitis. The Asthma Segment held the largest Ciclesonide market share in 2021. This growth is owing to the rising pervasiveness of asthma most likely ascribed to genetic or environmental factors. In people with asthma, the ciclesonide mechanism of action involves the elimination of inflammation within the airways. The expanding application of ciclesonide to avert and decrease the symptoms of asthma is further propelling the growth of the Asthma segment.

Furthermore, the Allergic Rhinitis segment is estimated to grow with the fastest CAGR of 3.0% during the forecast period 2022-2027 owing to the increasing predominance of allergic rhinitis attributed to the overreaction of the immune system to some substances termed allergens which could be outdoor or indoor allergens, irritants like cigarette smoke or concealed food allergens.

Ciclesonide Market Segment Analysis - by End-user

The Ciclesonide Market based on end-user can be further segmented into Adults and Children. The Adults Segment held the largest Ciclesonide market share in 2021. This growth is owing to the surging application of ciclesonide to avert asthma attacks in mature grown-ups. Ciclesonide is a novel steroid that is recorded to prepare lower active steroids until the medication arrives at the lung on inhalation leading to decreased possibility of throat symptoms. The heightening application of ciclesonide nasal spray for the treatment of allergic rhinitis is further propelling the growth of this segment. Furthermore, the Children segment is estimated to grow with the fastest CAGR of 3.1% during the forecast period 2022-2027 owing to the safe and effective application of ciclesonide nasal spray for children with perennial allergic rhinitis and to avert asthma attacks in children aged at least 12 years.

Ciclesonide Market Segment Analysis - by Geography

The Ciclesonide Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Ciclesonide Market) held the largest Ciclesonide market share with 35% of the overall market in 2021. The growth of this region is owing to the increasing predominance of asthma and allergy rhinitis in the North American region. The surging medication launches are further propelling the growth of the Ciclesonide Industry, thereby contributing to the Ciclesonide Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the extensive application of ciclesonide to handle symptoms of long-term allergies and asthma in the Asia-Pacific region. The enormous patient pool is further fuelling the progress of the Ciclesonide Market in the Asia-Pacific region.

Ciclesonide Market Drivers

Surging Investigations on Ciclesonide are Projected to Drive the Growth of the Ciclesonide Market:

Ciclesonide is undergoing phase III investigations in the U.S. It is thought of as a third-generation inhaled glucocorticoid owing to the numerous rare features that differentiate it from additional members of the class. As it is present in the canister, ciclesonide is in an inactive form. Once it arrives in the lung, it is metabolized by lung esterases to its active form, des ciclesonide. Des ciclesonide has great glucocorticoid receptor binding affinity and is inclined to exhibit important anti-inflammatory impacts. Des ciclesonide is 99% protein bound. The surging investigations on ciclesonide are therefore fuelling the growth of the Ciclesonide Market during the forecast period 2022-2027.

Soaring Significance of Ciclesonide Brand Names is Expected to Boost the Growth of the Ciclesonide Industry:

The products accessible in the U.S. that include ciclesonide and contribute to the growth of the ciclesonide market in the U.S. involve Ciclesonide brand names termed Alvesco, Omnaris and Zetonna. Alvesco includes ciclesonide systemic belonging to the drug class of inhaled corticosteroids. Ciclesonide systemic is applied in the treatment of asthma and in asthma maintenance. Ciclesonide nasal is marketed under ciclesonide brand names termed Omnaris and Zetonna. It belongs to the drug class of nasal steroids and is utilized in the treatment of Allergic Rhinitis. Considering the ciclesonide price, the price for Omnaris nasal spray (50 mcg/inh) is about $320 for a supply of 12.5 grams, relying on the pharmacy one visit. The soaring significance of ciclesonide brand names is driving the growth of the Ciclesonide Industry, thereby contributing to the Ciclesonide Industry Outlook during the forecast period 2022-2027.

Ciclesonide Market Challenges

Limitations of Ciclesonide are Hampering the Growth of the Ciclesonide Market:

The ciclesonide mechanism of action involves the body transforming ciclesonide to des-ciclesonide, which is the active form of the medication. Glucocorticoid steroids have powerful anti-inflammatory activities. “The percentage of ciclesonide and des-ciclesonide bound to human plasma proteins averaged 99% each, with 1% of unbound drug detected in the systemic circulation”. Ciclesonide inhalation will not perform sufficiently fast to treat an asthma attack. A fast-acting inhalation medication needs to be utilized for an asthma attack. Ciclesonide side effects on inhalation include hives, hardship in breathing and swelling of the face, lips, tongue or throat. These issues are thus hampering the growth of the Ciclesonide Market.

Ciclesonide Industry Outlook

Novel product launches, strategic mergers and acquisitions, strategic alliances and R&D activities are key strategies players in the Ciclesonide Market adopt. The top 10 companies in the Ciclesonide Market are:
  1. AstraZeneca Plc.
  2. Cipla Limited
  3. Sun Pharmaceutical Industries Ltd.
  4. Apotex Inc.
  5. Covis Pharma
  6. Bionique Pharma
  7. Takeda Pharmaceuticals International GmbH
  8. Sunovion Pharmaceuticals Inc.
  9. Nycomed Canada Inc.
  10. Teijin Pharma.

Recent Developments

  • In May 2022, Cipla introduced the 'RT Direct' Multiplex real-time PCR kit for Covid-19. Cipla declared the commercialization of the ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India. This was performed in partnership with Genes2Me Pvt. Ltd.
  • In October 2021, AstraZeneca introduced Clinical Data and Insights division in India. It extended its footprint in the nation. The Clinical Data & Insights team in Bengaluru, India, is crucial progress to back a burgeoning global portfolio.
  • In December 2020, Cipla introduced the ‘CIPtest’ Rapid Antigen Detection Test for COVID-19 Diagnosis. The firm will initiate supply this week. This is Cipla’s second introduction to the diagnostics space.

Relevant Reports:

Report Code: HCR 0876

Report Code: HCR 84738

Report Code: HCR 41227

For more Lifesciences and Healthcare Market reports, please click here
1. Ciclesonide Market Overview
    1.1 Definitions and Scope
2. Ciclesonide Market - Executive Summary
3. Ciclesonide Market – Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Ciclesonide Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Ciclesonide Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Ciclesonide Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Ciclesonide Market – Strategic Analysis
    7.1 Value Chain Analysis 
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Ciclesonide Market – by Indication (Market Size – $Million/$Billion) 
    8.1 Asthma
    8.2 Allergic Rhinitis
9. Ciclesonide Market – by End-user (Market Size – $Million/$Billion) 
    9.1 Adults
    9.2 Children
10. Ciclesonide Market - by Geography (Market Size - $Million/Billion)
    10.1 North America
        10.1.1 the U.S.
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 Germany
        10.2.2 France
        10.2.3 the UK
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Japan
        10.3.3 South Korea
        10.3.4 India
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 Rest of South America
    10.5 Rest Of The World
        10.5.1 the Middle East
        10.5.2 Africa
11. Ciclesonide Market - Market Entropy
    11.1 New product launches
    11.2 M&A's, collaborations, JVs and partnerships
12. Ciclesonide Market – Industry Competition Landscape (Premium)
    12.1 Market Share Analysis
        12.1.1 Market Share by Region – Key Companies
        12.1.2 Market Share by Countries – Key Companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Ciclesonide Market – Key Company List by Country Premium (Premium)
14. Ciclesonide Market - Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
* "Financials would be provided to private companies on a best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.

LIST OF TABLES

1.Global Ciclesonide Market, by Type Market 2019-2024 ($M)
2.Global Ciclesonide Market Analysis and Forecast by Type and Application Market 2019-2024 ($M)
3.Global Ciclesonide Market, by Type Market 2019-2024 (Volume/Units)
4.Global Ciclesonide Market Analysis and Forecast by Type and Application Market 2019-2024 (Volume/Units)
5.North America Ciclesonide Market, by Type Market 2019-2024 ($M)
6.North America Ciclesonide Market Analysis and Forecast by Type and Application Market 2019-2024 ($M)
7.South America Ciclesonide Market, by Type Market 2019-2024 ($M)
8.South America Ciclesonide Market Analysis and Forecast by Type and Application Market 2019-2024 ($M)
9.Europe Ciclesonide Market, by Type Market 2019-2024 ($M)
10.Europe Ciclesonide Market Analysis and Forecast by Type and Application Market 2019-2024 ($M)
11.APAC Ciclesonide Market, by Type Market 2019-2024 ($M)
12.APAC Ciclesonide Market Analysis and Forecast by Type and Application Market 2019-2024 ($M)
13.MENA Ciclesonide Market, by Type Market 2019-2024 ($M)
14.MENA Ciclesonide Market Analysis and Forecast by Type and Application Market 2019-2024 ($M)

LIST OF FIGURES

1.US Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
2.Canada Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
3.Mexico Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
4.Brazil Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
5.Argentina Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
6.Peru Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
7.Colombia Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
8.Chile Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
9.Rest of South America Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
10.UK Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
11.Germany Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
12.France Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
13.Italy Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
14.Spain Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
15.Rest of Europe Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
16.China Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
17.India Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
18.Japan Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
19.South Korea Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
20.South Africa Global Ciclesonide Industry Market Revenue, 2019-2024 ($M)
21.North America Global Ciclesonide Industry By Application
22.South America Global Ciclesonide Industry By Application
23.Europe Global Ciclesonide Industry By Application
24.APAC Global Ciclesonide Industry By Application
25.MENA Global Ciclesonide Industry By Application